New Onset clinical trials at UCLA

1 in progress, 0 open to eligible people

Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes
Sorry, not currently recruiting here
This multi-center randomized controlled trial will assess the safety and efficacy of ATG followed by either adalimumab or verapamil in preserving insulin secretion 2 years from randomization in persons aged 9 to <21 with recent-onset stage 3 T1D.
Los Angeles, California and other locations

Our lead scientists for New Onset research studies include Christina Reh, MD.

Last updated: October 12, 2026

Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes